Skip to main content

2018

March 02, 2019
This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Background: Patient Health Questionnaire-9 (PHQ-9) is a validated patient self-administrated…
March 02, 2019
This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Background: A survey was carried out to investigate the relative importance of antipsychotic…
March 02, 2019
This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Sexual dysfunction may be associated with major depressive disorder (MDD) or with…
March 02, 2019
This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Background: There is limited literature on treatment patterns, healthcare resource…
March 02, 2019
This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida.
March 02, 2019
This poster was presented at the 30th annual Psych Congress, held Sept. 16-19, 2017, in New Orleans, Louisiana. Traditional measures of MDD treatment response may miss meaningful changes for…
March 02, 2019
This Phase 4 open-label trial evaluated real-world effectiveness of the antidepressant vortioxetine on the ability of patients with MDD to achieve pre-identified treatment goals.
March 02, 2019
Background: Most people with depression do not achieve adequate treatment response. People’s perceptions of their depression and treatment outcomes are crucial to understanding challenges they endure…
March 02, 2019
Introduction: Despite increased nonmedical use of ADHD prescription stimulants, there are limited data to inform selection of intranasal doses for abuse-potential evaluations. This study determined a…
March 02, 2019
Treatment-resistant schizophrenia (TRS) occurs in up to 30% of patients with schizophrenia and is defined as the persistence of positive symptoms despite ≥2 trials of antipsychotic (AP) medications…
Back to Top